Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Grants Priority Review to Zasocitinib for Moderate-to-Severe Plaque Psoriasis

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at dermatologytimes.com →

◆ Verified

Fusion42 · 14 September 2026 · Fusion42 review

The US FDA has granted Priority Review to Takeda’s oral TYK2 inhibitor, zasocitinib, for treating moderate-to-severe plaque psoriasis based on positive phase 3 LATITUDE trial results showing significant skin clearance and tolerability.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face new competition in oral psoriasis treatments as Takeda’s oral TYK2 inhibitor nears US approval, challenging existing therapies with strong trial results. You should act now to assess your product positioning against a potential market leader delivering faster and broader skin clearance.

◆ Coverage

1 source · 14 Sep 2026

◆ Related on Wire

◆ Topics

BiotechFDA-priority-reviewpsoriasisoral-therapyclinical-trialstyk2-inhibitor